190 related articles for article (PubMed ID: 33490265)
1. KIF11 Promotes Proliferation of Hepatocellular Carcinoma among Patients with Liver Cancers.
Hu ZD; Jiang Y; Sun HM; Wang JW; Zhai LL; Yin ZQ; Yan J
Biomed Res Int; 2021; 2021():2676745. PubMed ID: 33490265
[TBL] [Abstract][Full Text] [Related]
2. Kinesin family member 11 promotes progression of hepatocellular carcinoma via the OCT4 pathway.
Zhang J; Wei Z; Qi X; Jiang Y; Liu D; Liu K
Funct Integr Genomics; 2023 Aug; 23(3):284. PubMed ID: 37648881
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.
Wang MR; Fang D; Di MP; Guan JL; Wang G; Liu L; Sheng JQ; Tian DA; Li PY
Int J Med Sci; 2020; 17(9):1224-1234. PubMed ID: 32547318
[No Abstract] [Full Text] [Related]
4. LncRNA NEAT1 suppresses cellular senescence in hepatocellular carcinoma via KIF11-dependent repression of CDKN2A.
Chen D; Wang J; Li Y; Xu C; Fanzheng M; Zhang P; Liu L
Clin Transl Med; 2023 Sep; 13(9):e1418. PubMed ID: 37752791
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-301b-3p contributes to tumour growth of human hepatocellular carcinoma by repressing vestigial like family member 4.
Guo Y; Yao B; Zhu Q; Xiao Z; Hu L; Liu X; Li L; Wang J; Xu Q; Yang L; Huang D
J Cell Mol Med; 2019 Aug; 23(8):5037-5047. PubMed ID: 31207037
[TBL] [Abstract][Full Text] [Related]
6. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F
J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927
[TBL] [Abstract][Full Text] [Related]
7. High KIF11 expression is associated with poor outcome of NSCLC.
Liu J; Tian Y; Yi L; Gao Z; Lou M; Yuan K
Tumori; 2022 Feb; 108(1):40-46. PubMed ID: 33554761
[TBL] [Abstract][Full Text] [Related]
8. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
Chen H; Wang H; Yu X; Zhou S; Zhang Y; Wang Z; Huang S; Wang Z
BMC Cancer; 2020 Sep; 20(1):853. PubMed ID: 32891122
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of hematological and neurological expressed 1 (HN1) is associated with a poor prognosis of hepatocellular carcinoma and its knockdown inhibits cell growth and migration partly by down-regulation of c-Met.
Chen JJ; Sun X; Mao QQ; Jiang XY; Zhao XG; Xu WJ; Zhong L
Kaohsiung J Med Sci; 2020 Mar; 36(3):196-205. PubMed ID: 31749294
[TBL] [Abstract][Full Text] [Related]
10. KIFC1 is activated by TCF-4 and promotes hepatocellular carcinoma pathogenesis by regulating HMGA1 transcriptional activity.
Teng K; Wei S; Zhang C; Chen J; Chen J; Xiao K; Liu J; Dai M; Guan X; Yun J; Xie D
J Exp Clin Cancer Res; 2019 Jul; 38(1):329. PubMed ID: 31340839
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
[TBL] [Abstract][Full Text] [Related]
12. cIAP2 via NF-κB signalling affects cell proliferation and invasion in hepatocellular carcinoma.
Jiang XJ; Chen ZW; Zhao JF; Liao CX; Cai QH; Lin J
Life Sci; 2021 Feb; 266():118867. PubMed ID: 33310033
[TBL] [Abstract][Full Text] [Related]
13. LncSNHG3 promotes hepatocellular carcinoma epithelial mesenchymal transition progression through the miR-152-3p/JAK1 pathway.
Li H; Wu Y; Wang R; Guo J; Yu Q; Zhang L; Zhao H; Yang H
Genes Genomics; 2022 Jan; 44(1):133-144. PubMed ID: 34778942
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29.
Du H; Xu Q; Xiao S; Wu Z; Gong J; Liu C; Ren G; Wu H
Life Sci; 2019 May; 224():1-11. PubMed ID: 30876939
[TBL] [Abstract][Full Text] [Related]
15. Cell division cycle associated 8: A novel diagnostic and prognostic biomarker for hepatocellular carcinoma.
Cui XH; Peng QJ; Li RZ; Lyu XJ; Zhu CF; Qin XH
J Cell Mol Med; 2021 Dec; 25(24):11097-11112. PubMed ID: 34741389
[TBL] [Abstract][Full Text] [Related]
16. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
[TBL] [Abstract][Full Text] [Related]
17. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
[TBL] [Abstract][Full Text] [Related]
19. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.
Ding Z; Ericksen RE; Escande-Beillard N; Lee QY; Loh A; Denil S; Steckel M; Haegebarth A; Wai Ho TS; Chow P; Toh HC; Reversade B; Gruenewald S; Han W
J Hepatol; 2020 Apr; 72(4):725-735. PubMed ID: 31726117
[TBL] [Abstract][Full Text] [Related]
20. ASPM combined with KIF11 promotes the malignant progression of hepatocellular carcinoma via the Wnt/β-catenin signaling pathway.
Wu B; Hu C; Kong L
Exp Ther Med; 2021 Oct; 22(4):1154. PubMed ID: 34504599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
